Vasospastic Angina: A Contemporary Review of its Pathophysiology, Diagnosis and Management

Aish Sinha1, Haseeb Rahman1, Divaka Perera1

  • 1The British Heart Foundation Centre of Excellence and the National Institute for Health and Care Research Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.

Heart International
|February 6, 2023
PubMed

Insights

Vasospastic angina (VSA), a cause of chest pain in nearly 40% of patients with non-obstructed coronary arteries (ANOCA), has poorly understood mechanisms and limited treatments. This review summarizes VSA pathophysiology, diagnostics, and current therapeutic options.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pathophysiology

Background:

  • Angina with non-obstructed coronary arteries (ANOCA) affects nearly 40% of patients undergoing cardiac catheterization.
  • Coronary artery spasm, a key cause of ANOCA, leads to vasospastic angina (VSA), impacting quality of life and increasing major adverse cardiac events.
  • The underlying mechanisms of VSA remain incompletely understood, limiting effective therapeutic strategies.

Purpose of the Study:

  • To provide a comprehensive review of the pathophysiological mechanisms of VSA.
  • To summarize current therapeutic options for patients with VSA.
  • To critically appraise the diagnostic approaches for suspected VSA.

Main Methods:

  • Literature review of recent research on ANOCA and VSA.
  • Synthesis of information on VSA pathophysiology, diagnosis, and treatment.
  • Critical appraisal of diagnostic and therapeutic strategies.

Main Results:

  • VSA is a distinct entity within the ANOCA spectrum, characterized by reversible coronary flow attenuation.
  • Current understanding of VSA pathophysiology is limited, contributing to a lack of targeted therapies.
  • A surge in research over the past decade has improved insights into VSA.

Conclusions:

  • Further research into VSA pathophysiology is crucial for developing improved therapeutic options.
  • Accurate diagnosis and timely management of VSA are essential for improving patient outcomes.
  • This review consolidates current knowledge, guiding future research and clinical practice in VSA.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
13
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
26
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
21
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
611
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
18
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
17